Contineum Therapeutics (CTNM) said late Thursday it priced its upsized underwritten public offering of about 7.3 million of class A shares at $12.25 apiece for gross proceeds of around $90 million.
The company has granted underwriters a 30-day option to purchase up to an additional 1.1 million class A shares at the offering price.
The offering is expected to close on Monday.